The PI3K-AKT pathway is frequently altered through biallelic loss of Pten and activating mutations in PI3K and AKT1 in primary and metastatic prostate cancer (Supplementary Fig. 7a)24. The gene discussed is PTEN; the disease is metastatic prostate carcinoma.